Novartis Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Using the BRAF-V600 tumor mutation as a marker, investigators identified pre-treatment and on-treatment ties between ctDNA and patient outcomes. Invitae, Pharma Firms Partner to Develop Standard MRD Panel for AML Clinical Trials Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials. Nonprofit Friends of Cancer Research Launches Public-Private HRD Harmonization Project The consortium aims to harmonize the use of homologous recombination deficiency as a biomarker to guide certain treatment types in cancer patients. FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Three Targeted Therapies FoundationOne Liquid CDx can now be used as a companion diagnostic for therapies to treat advanced ovarian, breast, and non-small cell lung cancer. FDA Approves Novartis' Capmatinib, Foundation Medicine CDx for Metastatic NSCLC The oral MET inhibitor, marketed as Tabrecta, is for patients whose tumors have a mutation that leads to MET exon 14 skipping as detected by a Foundation Medicine test. Dec 4, 2019 FDA Approves Foundation Medicine CDx for Novartis Breast Cancer Drug Piqray Nov 19, 2019 Double Mutations in PIK3CA Gene Increase Patient Sensitivity to Targeted Therapies, Study Finds Premium Nov 7, 2019 Colorectal Cancers Dial up Mutability in Response to Targeted Treatments Oct 21, 2019 SomaLogic Expands Agreement With Novartis Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Jun 18, 2019 Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms Premium May 24, 2019 FDA Approves Qiagen's PIK3CA Test as Companion Test for Novartis Breast Cancer Drug Feb 14, 2019 AbCellera, Novartis Partner on Antibody Drug Discovery Dec 7, 2018 Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing Premium Dec 6, 2018 Qiagen to Develop Companion Dx for Novartis Breast Cancer Drug Nov 13, 2018 Health Canada Approves Two BCR-ABL Tests Oct 30, 2018 Precision Oncology Highlights From ESMO 2018 Oct 17, 2018 Foundation Medicine, Novartis Partner to Develop CDx for Oncology Drugs Aug 1, 2018 New Lung Cell Type Linked to Cystic Fibrosis Emerges From Mouse, Human Cell Atlas Studies Jun 4, 2018 MolecularMD, Genoptix Ink Marketing Agreement for CDx to Novartis CML Drug Feb 6, 2018 Quest to Offer Thermo Fisher's Oncomine Dx Target Test Dec 27, 2017 MolecularMD Gets FDA Authorization for Companion Dx to Novartis CML Drug Nov 27, 2017 European Consortium Aims to Deliver New Tests, Therapies for Cardiovascular Diseases Premium Nov 7, 2017 Roche ALK Test Gains FDA Approval as CDx for Alecensa Oct 12, 2017 NIH Partners With Biopharmaceutical Firms on $215M Cancer Immunotherapy Research Initiative Load More Breaking News Enzo Biochem, CLX Health Partner to Support COVID-19 Testing for International Travel Type 1 Diabetes GWAS, Fine-Mapping Leads to New Genetic Loci, Potential Drug Targets LSU Health Sciences Center Wins $2.4M to Lead SARS-CoV-2 Variant Sequencing Program NanoString Technologies, Parker Institute for Cancer Immunotherapy Partner on Cell Therapy Project BGI Americas Collaborating With Champions Oncology on Proteomic Cancer Research Personal Genome Diagnostics Inks Cancer Genomic Profiling Deal with Duke University Health System The Scan Missed Early Cases A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports. Limited Journal Editor Diversity A survey finds low diversity among scientific and medical journal editors, according to The Scientist. How Much of a Threat? Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned. PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.